Limfjords Bio ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  14.4% 7.8% 8.7% 7.9% 8.4%  
Credit score (0-100)  16 31 27 30 28  
Credit rating  BB BB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  1,052 405 87.1 137 665  
EBITDA  1,052 405 87.1 137 665  
EBIT  1,052 405 87.1 137 665  
Pre-tax profit (PTP)  1,051.7 385.1 12.0 92.4 591.1  
Net earnings  818.0 300.4 9.1 72.1 460.9  
Pre-tax profit without non-rec. items  1,052 385 12.0 92.4 591  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  868 350 59.1 131 592  
Interest-bearing liabilities  0.0 4,828 4,489 10,195 2,955  
Balance sheet total (assets)  1,414 5,571 4,738 10,758 3,687  

Net Debt  -28.5 4,828 4,489 10,195 2,955  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  1,052 405 87.1 137 665  
Gross profit growth  0.0% -61.5% -78.5% 57.2% 385.6%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  1,414 5,571 4,738 10,758 3,687  
Balance sheet change%  0.0% 294.0% -15.0% 127.0% -65.7%  
Added value  1,051.7 405.2 87.1 136.9 664.6  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 4.0 5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  74.4% 12.1% 2.3% 2.4% 9.2%  
ROI %  121.2% 14.0% 2.5% 2.5% 9.6%  
ROE %  94.2% 49.3% 4.4% 75.8% 127.5%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  61.4% 6.3% 1.2% 1.2% 16.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -2.7% 1,191.5% 5,154.1% 7,448.8% 444.6%  
Gearing %  0.0% 1,378.0% 7,601.6% 7,775.9% 499.2%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 1.6% 2.3% 1.2% 1.1%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  2.6 0.8 0.8 0.6 0.8  
Current Ratio  2.6 1.1 1.0 1.0 1.2  
Cash and cash equivalent  28.5 0.0 0.0 0.0 0.0  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  868.0 350.4 59.1 131.1 592.0  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0